Neuralstem President and CEO to Present 2013 Trials Overview at 2013 Biotech Showcase
Updates on Upcoming ALS Phase II - NSI-189 Phase Ib - Stroke Phase I/II in China
Live Audio Webcast to Air on Tuesday, January 8, at 3:45 p.m. PT
ROCKVILLE, Md., Jan. 4, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the fifth annual Biotech Showcase in San Francisco on Tuesday, January 8, 3:45 p.m. PT, in Room Powell. Garr will present a business overview, including a first look at the Phase I/II Stroke/NSI-566 cell therapy trial expected to commence in Beijing within several weeks. Garr will also provide an update on the company's ALS cell therapy trial and plans for the Phase II. The trial's investigators recently announced a substantial grant for the Neuralstem ALS Phase II trial from the National Institutes of Health (NIH). Garr will also update the trial progress of its first-in-class neurogenic NSI-189 small molecule drug which stimulates new neuron growth in the hippocampus, currently in a Phase Ib major depressive disorder (MDD) trial.
The audio webcast will be available in real-time at http://www.media-server.com/m/p/y46fee25 and archived for one year. The webcast link will also be posted on the Investor Center home page on Neuralstem's website: www.neuralstem.com.
The 2013 Biotech Showcase will be held at the Parc 55 Wyndham Hotel in San Francisco, January 7-9. For more information, see: http://www.ebdgroup.com/bts/index.php.
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed dosing of the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, in August 2012; the trial ends six months after that last surgery. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.
In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.
Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress disorder (PTSD).
For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended September 30, 2012.
SOURCE Neuralstem, Inc.
More by this Source
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
May 10, 2013, 16:24 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.